ESMO BREAST CANCER CONGRESS 2023 Date: 11-13 May 2023 Venue: Messe Berlin, Berlin, Germany ESMO Breast Cancer 2023 will take place on 11-13 May 2023 in Berlin, Germany. Cancer patients and their needs are at the heart of what we do – we are committed to advancing research and integrati...
Breast Cancer: Early Stage - Hormone Receptor Positive Breast Cancer: Early Stage - Other Breast Cancer: Early Stage - Triple Negative Breast Cancer: Metastatic - HER2+ Breast Cancer: Metastatic - Hormone Receptor Positive Breast Cancer: Metastatic - Other Breast Cancer: Metastatic - Triple Negative...
Explore breast cancer research in npj Breast Cancer, an open access journal with 6.5 Impact Factor and 7 days to first decision.
Let us meet again @ Breast Cancer 2025 For More details visit: https://breastcancer.conferenceseries.com/ Past Reports Gallery To Collaborate Scientific Professionals around the World Conference Date May 26-27, 2025 For Sponsors & Exhibitors sponsor@conferenceseries.com Speaker Opportunity Poster ...
《乳腺癌》(Breast Cancer)是一本由Springer Japan出版的以ONCOLOGY-OBSTETRICS & GYNECOLOGY为研究特色的国际期刊,发表该领域相关的原创研究文章、评论文章和综述文章,及时报道该领域相关理论、实践和应用学科的最新发现,旨在促进该学科领域科学信息的快速交流。该期刊
Abstract Title: “Synergistic Activity of CDK8/19 Inhibitor RVU120 and MEK Inhibitors in Hormone-Negative Breast Cancer: Implications for Targeted Therapy” Session Name:Poster Session 4 Session date and time:Thursday, December 7, 2023, 5:00 PM - 7:00 PM CT ...
The tumour immune microenvironment is shaped by the crosstalk between cancer cells, immune cells, fibroblasts, endothelial cells and other stromal components. Although the immune tumour microenvironment (TME) serves as a source of therapeutic targets, it
ABC7 - Seventh Advanced Breast Cancer International Consensus Conference Date: 9-11 November 2023 Location: Lisboa, Portugal Organised by: ABC Global Alliance 、 European School of Oncology (ESO) 摘要征文投稿: Deadline for submission:17 May 2023 ...
Furthermore, it has been reported at the 2023 San Antonio Breast Cancer Symposium that inavolisib, another PI3K inhibitor, was more effective than placebo when combined with palbociclib and fulvestrant in the first-line treatment of patients withPIK3CA-mutated, HR-positive, HER2-negative, locally ...
et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet 55, 1696–1708 (2023). https://doi.org/10.1038/s41588-023-01507-7 Download citation Received19 June 2022 Accepted21 August 2023 Published28 September 2023 Issue DateOctober 2023 DOIhttps://doi....